Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Drug Makers Introduce New Drugs To Thwart Asthma Drug Caps

This article was originally published in PharmAsia News

Executive Summary

Major drug makers in India are producing new brands of a popular asthma drug in an effort to avoid the nation's price controls. Cipla, Dr. Reddy's, Ranbaxy and Zydus Cadila have brought out new brands based on doxopthyline, a derivative of theophyline, which is subject to controls. The move is being made even though doxopthyline is considered less effective, because the makers can fetch a higher price. Dr. Reddy's introduced its Doxobid, Macleods its Doxoril, Ranbaxy its Synasma and Zydus its Doxolin within the past year or so, none subject to price controls. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts